Medical Sciences. In the article ''Core binding factor ␤-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells'' by Cisca Wijmenga, Paula E. Gregory, Amitav Hajra, Evelin Schröck, Thomas Ried, Roland Eils, P. Paul Liu, and Francis S. Collins, which appeared in number 4, February 20, 1996 , of Proc. Natl. Acad. Sci. USA (93, (1630) (1631) (1632) (1633) (1634) (1635) , the authors request that the following be noted. ''The basic conclusion of this paper, that the CBF␤-SMMHC chimeric protein forms nuclear rod-like structures in NIH 3T3 cells in which the protein is overexpressed, appears correct. However, the data shown in Figs. 3, 5, and 6, involving deletions of the chimeric protein, should be disregarded.'' Vmax is the maximum actin-activated ATPase activity of HMM and Ka is the apparent binding constant for HMM to actin, which is defined to be the reciprocal of the apparent Km from the double reciprocal plots (Fig. 4) . To phosphorylate the regulatory light chain of HMM, myosin light chain kinase, calmodulin, and Ca 2ϩ were added to the ATPase assay medium. -, Not measured.
Proc. Natl. Acad. Sci (19) . Immunohistochemical evidence has been obtained indicating that GLUTI is highly expressed in breast cancer cells compared to their normal counterparts, but no apparent changes in the expression of GLUT2 were detected (19 (30.6 Ci per mmol; DuPont/NEN). Up- take was stopped by washing the cells with ice-cold phosphatebuffered saline (PBS). Cells were dissolved in 0.5 ml of lysis buffer (10 mM Tris HCl, pH 8.0/0.2% SDS), and the incorporated radioactivity was assayed by liquid scintillation spectrometry. Where appropriate, competitors and inhibitors were added to the uptake assays or preincubated with the cells. Fructose uptake assays were performed in incubation buffer Immunoblotting was performed as described (23) using anti-GLUT antibodies (East Acres Biologicals, Southbridge, MA) and horseradish peroxidase goat anti-rabbit IgG and enhanced chemiluminescence (Amersham). For immunocytochemistry, cells were grown on eight-well microscope slides, fixed with buffered formaldehyde/acetone, washed with PBS, and incubated in PBS containing 5% bovine serum albumin (BSA) followed by incubation for 1 h at room temperature in the same buffer containing 1% BSA, 0.3% Triton X-100, and Abbreviation: PET, positron emission tomography. STo whom reprint requests should be addressed.
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anti-GLUT antibodies (1:100) or rabbit preimmune serum. Cells were then incubated with fluorescein isothiocyanate goat anti-rabbit IgG (Life Technologies; 1:40) for 1 h, mounted, and analyzed by fluorescence microscopy. Breast tissue expression of GLUT5 was determined by immunohistochemical analysis of a set of thin sections prepared from archived paraffin tissue blocks. Paraffin was removed by incubating the sections in xylene followed by absolute alcohol and then the sections were hydrated by immersion in graded alcohol solutions. Sections were incubated in PBS containing 5% skim milk, washed with PBS, and incubated with the anti-GLUT antibodies (1:100) for 2 h. After extensive washing with PBS, sections were incubated for 1 h with alkaline phosphatase goat anti-rabbit IgG (1:500) and color developed with 4-nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate.
RESULTS
We measured the uptake of deoxyglucose, an analog of glucose transported only by the facilitative glucose transporters (8) , in MCF-7 and MDA-468 cells. These cell lines are widely used to characterize the behavior of human breast cancer in vitro and in vivo (24) . Both cell lines showed a notable capacity to take up deoxyglucose (Fig. 1A) Fig. 1 B and C) or from Eadie-Hofstee plots (data not shown) revealed the presence of two functional components with separate affinities for uptake of deoxyglucose in both cell lines-a high-affinity component with an apparent Km for transport of 2 mM and a second component of lower affinity with an apparent Km for transport of 10 mM. When we measured uptake of deoxyglucose at very short intervals, from 5 sec to 2 min, the rate of uptake of deoxyglucose by MDA-468 cells was 3-fold higher than that of MCF-7 cells (Fig. 1D) . Therefore, the 5-fold difference in uptake observed in long-term uptake experiments (Fig. 1A ) reflects a step secondary to transport, most likely the intracellular trapping of deoxyglucose as deoxyglucose 6-phosphate (8) . Kinetic analysis using Lineweaver-Burk ( Fig. 1 E and F) or Eadie-Hofstee (data not shown) plots confirmed the presence of two functionally distinct glucose transporters in the breast cancer cells. Using the Michaelis expression for a single-substrate reaction under conditions of initial velocity (25), we estimated that at a glucose concentration of 5.5 mM, the high-affinity system comprises three-quarters of the capacity of the breast carcinoma cell lines to take up glucose ( fructose because GLUT2 is able to transport fructose in addition to glucose (26) . Both cell lines were able to take up fructose ( Fig. 2A) , and uptake was linear for approximately the first 60 sec. In long-term uptake studies, we observed that fructose uptake by MDA-468 cells was -5-fold greater than in MCF-7 cells. At short uptake times the difference was only 2-fold, similar to that observed for transport of deoxyglucose. Lineweaver-Burk analysis of the transport of fructose revealed two fructose transport activities-a high-affinity component with an apparent Km of 10 mM for fructose transport in both MCF-7 and MDA-468 cells (Fig. 2 B and C) and a low-affinity pathway that showed no saturation at concentrations of fructose as high as 50 mM (data not shown). The value of 10 mM is 1 order of magnitude lower than the values previously described for transport of fructose by GLUT2 (26) . At concentrations of fructose lower than 10 mM, the high-affinity pathway contributed >90% of the capacity of the MCF-7 (Fig.  2D ) and MDA-468 (Fig. 2E) cells to transport fructose.
These data suggested the presence of the fructose transporter GLUT5 in MCF-7 cells. GLUT5 has a Km for the transport of fructose of 6 mM, is not inhibited by cytochalasin B, a specific inhibitor of the facilitative hexose transporters, and does not transport deoxyglucose (14) . In MCF-7 cells, transport of deoxyglucose was completely inhibited by cytochalasin B but not by cytochalasin E, an analog of cytochalasin B that does not interact with the glucose transporters (8) (Fig. 2F) . Fifty percent inhibition was observed at 0.4 ,tM cytochalasin B, a value that falls between the value of the K1 for GLUT1 (-0.2 ,uM) and the Ki for GLUT2 (-2 ,uM) (27) . On the other hand, 100 ,uM cytochalasin B inhibited <40% of fructose uptake, and <20% inhibition was observed with 1 ,uM cytochalasin B (Fig. 2G) . Cytochalasin E did not interfere with the transport of fructose. It is known that fructose can completely inhibit the uptake of deoxyglucose mediated by GLUT2 (26) . At 10 mM fructose, the transport of deoxyglucose was not substantially affected, and at 100 mM fructose there was only -30% inhibition of deoxyglucose uptake (Fig.  2H) . These results suggest that GLUT2 likely corresponded to the low-affinity pathway. As controls we used L-glucose (8), a sugar that is not transported by the facilitative glucose transporters and did not inhibit the transport of deoxyglucose by the MCF-7 cells, and deoxyglucose, which competed for 12 1 [3H]deoxyglucose uptake completely at 100 mM (Fig. 2H ).
Previous data indicated that deoxyglucose is able to inhibit completely the uptake of fructose mediated by GLUT2 but does not affect fructose uptake mediated by GLUT5 (14) . Deoxyglucose (100 mM) inhibited <20% of fructose uptake (Fig. 21) , contrasted with the effect of 100 mM fructose, which inhibited [3H]fructose uptake completely (Fig. 21) .
The presence of GLUT1, GLUT2, and GLUTS in the human breast cancer cell lines was confirmed by immunoblotting and immunolocalization with anti-glucose transporter antibodies. Immunoblotting experiments revealed the presence of several overlapping anti-GLUT1 immunoreactive bands in total cell homogenates from both cell lines (Fig. 3) . Bands of 45-80 kDa were labeled in the MCF-7 cells, compared to bands of 60-90 kDa in the MDA-468 cells. The anti-GLUT1 antibody reacted with a band of -45 kDa in an immunoblot of human erythrocyte proteins (data not shown). GLUT2 was also expressed in both breast cancer cell lines (Fig.  3) . Anti-GLUT2 antibodies reacted with several bands of 46-90 kDa and differences in the intensities of the various bands were observed depending on the cell line. The anti-GLUT2 antibody reacted with a unique band of -50 kDa in an immunoblot of total liver proteins (data not shown). GLUT5 was also expressed in the MCF-7 and MDA-468 cell lines (Fig. 3) . Bands of 50-70 kDa were labeled in the MCF-7 cells, compared to bands of 50-85 kDa in the MDA-468 cells. Proteins from human testis showed a broad band of 40-60 kDa when immunoblotted with the anti-GLUT5 antibody (data not shown). No reactivity was observed when the blots were incubated with an anti-GLUT3 antibody, whereas GLUT4 was present in very small amounts in the two breast cancer cell lines (Fig. 3) . GLUT3 reacted with a unique 50-kDa band present in human sperm proteins and GLUT4 reacted with a 40-to 50-kDa band from human adipose tissue (data not shown). Immunolocalization studies using immunofluorescence confirmed the presence of the transporters GLUT1, GLUT2, and GLUT5 in the breast cancer cell lines (Fig. 4) . Most of the fluorescence was associated with the cytoplasm adjacent to the nucleus and the plasma membrane, and the staining was most intense in cells probed with the anti-GLUT1 and anti-GLUT5 antibodies. Cellular staining with anti-GLUT2 antibodies was weaker than with anti-GLUT1 or anti-GLUT5 antibodies and was clearly stronger in MDA-468 than in MCF-7 cells (Fig. 4) . Proc. Natl. Acad. Sci. USA 93 (1996) was detected in cells reacted with anti-GLUT3 antibodies or preimmune serum (Fig. 4) .
The results of immunoblotting and immunofluorescence experiments were concordant with the results of the transport studies and indicate that the breast cancer cell lines MCF-7 and MDA-468 express high levels of the transporters GLUT1, GLUT2, and GLUT5. The presence of the high-affinity fructose transporter GLUT5 in breast cancer cell lines was surprising since this transporter is believed to have a restricted cell and tissue distribution (13, 14, 28) . The finding suggested that the expression of GLUT5 in these cells could be related to the neoplastic state. We therefore tested for expression of GLUT5 in normal and neoplastic primary human breast tissue. All 20 primary breast cancer tissues tested were positive for expression of GLUT5 (Fig. 5 B and C; data not shown). Strong staining was seen in the perinuclear region, cytoplasm, and cell membrane of tumor cells. Staining was also seen in malignant cells invading the fibroadipose tissue. There was no staining of normal mammary tissue, indicating that normal mammary epithelium does not express GLUT5 ( Fig. 5A; data not shown) . No staining was observed in breast cancer tissue probed with preimmune serum. In control experiments, anti-GLUT1 staining was stronger in breast cancer tissue compared to normal breast tissue, consistent with overexpression of GLUT1 in the neoplastic cells (data not shown). Thus, while GLUT1 is present in normal breast and is overexpressed in breast cancer, GLUT5 is absent in normal breast tissue and is expressed at high levels in human breast cancer.
DISCUSSION
Our data indicate that the breast carcinoma cell lines MCF-7 and MDA-468 express three members of the facilitative hexose transporter family, the glucose transporters GLUT1 and GLUT2, and the high-affinity fructose transporter GLUT5. Deoxyglucose uptake and competition experiments in the cell lines indicated the presence of two functionally distinct glucose transport systems with the characteristics expected for GLUT1 and GLUT2, with apparent Km values of 2 and 10 mM for the transport of deoxyglucose, respectively. Fructose uptake and competition experiments indicated the presence in breast carcinoma cell lines of a high-affinity transporter of fructose functionally similar to GLUT5 (apparent Km, 8 mM) and a low-affinity pathway that failed to saturate at fructose concentrations as high as 50 mM functionally similar to GLUT2 (Km > 50 mM). The presence of GLUT1, GLUT2, and GLUT5 in the breast carcinoma cell lines was confirmed by immunoblotting and immunolocalization experiments, which also revealed a low level of expression of GLUT4 and no expression of GLUT3.
We found that GLUT1 and GLUT2 were present in normal and neoplastic breast tissue but that GLUT5 was expressed in human breast cancer and was absent from normal human breast tissue. Enhanced uptake and metabolism of glucose is a common characteristic of cancer cells and involves increased expression of GLUT1 in neoplasia (2, (16) (17) (18) (19) (14, 26) and GLUT2 is also capable of transporting glucose (26, 27, 29) . GLUT2 is expressed in liver, pancreatic 3 cells, the basolateral surface of kidney and small intestine epithelia (10, 30) , and in normal breast tissue (19) . GLUT5 does not transport glucose (14) and is expressed in small intestine, sperm cells, and brain (31, 32) , with very low level expression in adipose tissue and muscle (13, 14, 28) . GLUT5 is also expressed in Caco-2 cells, a human colon cancer cell line that differentiates in culture into cells with the properties of small intestine enterocytes (33) . GLUT5 transports fructose with high affinity (14) , whereas GLUT2 transports this sugar with very low affinity (26) . At the low concentrations of fructose present in vivo, GLUT5 is likely to mediate a high fraction (>90%) of the uptake of fructose due to the order of magnitude difference in the respective Km for transport of fructose by GLUT2 and GLUT5. These findings suggest an important role for GLUT5 in cellular uptake of fructose by breast cancer cells compared to normal breast tissue in which transport of fructose is mediated by GLUT2. Our results indicate that neoplastic transformation of breast epithelial cells leads to expression of a high-affinity fructose transporter permitting enhanced uptake of fructose, a substrate apparently used by few human tissues. Based on the Warburg theory, we can speculate that fructose may be a good substrate for energy generation in malignant cells that prefer the glycolytic pathway since lactic acid generation through fructolysis may not be subjected to the regulatory steps that control glucolysis. The fructolysis pathway may provide the neoplastic breast cancer cells with a metabolic advantage. These results suggest that fructose uptake could represent a useful target for PET imaging and possibly the development of novel therapeutic agents in breast cancer.
